Postmenopausal smokers show reduced hemodynamic benefit from oral hormone replacement

Am J Cardiol. 2000 Sep 1;86(5):590-2, A10. doi: 10.1016/s0002-9149(00)01027-4.

Abstract

With use of a randomized, placebo-controlled trial, 62 healthy, postmenopausal smokers and nonsmokers were tested for resting and stress-induced hemodynamic variables before and after 6 months of treatment with either oral hormone replacement therapy or placebo. Smokers had significantly less reduction in both resting and stress-induced vascular resistance and blood pressure after treatment with oral hormone replacement therapy than nonsmokers.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Blood Pressure / drug effects
  • Double-Blind Method
  • Estrogens, Conjugated (USP) / pharmacology*
  • Female
  • Hemodynamics / drug effects*
  • Hormone Replacement Therapy*
  • Humans
  • Medroxyprogesterone / pharmacology
  • Postmenopause / physiology*
  • Smoking / physiopathology*
  • Vascular Resistance / drug effects

Substances

  • Estrogens, Conjugated (USP)
  • Medroxyprogesterone